Harmony Biosciences Holdings Inc（HRMY）资讯与事件HRMYHarmony Biosciences Holdings Inc

Harmony Biosciences Reports Q2 Revenue of $261.28M

Reports Q2 revenue $261.28M, consensus $253.27M. "Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year. With this strong foundation, we are aggressively advancing our pipeline, with our orexin-2 agonist BP-205 as the centerpiece, that we believe can create significant long-term value for both patients and shareholders," said Jeffrey M. Dayno, MD, President and Chief Executive Officer of Harmony Biosciences. "The Phase 1 clinical PK and safety/tolerability data for BP-205 that we shared today, together with pre-clinical data demonstrating the highest potency of any orexin-2 agonist currently in the clinic, reinforce our conviction that BP-205 has the potential to be the best-in-class orexin-2 agonist with broad clinical utility across multiple CNS indications."

Harmony Biosciences Expects Full-Year Net Revenue of $1.0 to $1.04 Billion

"Our record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business," said Jeffrey Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. "Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in our ability to achieve full-year net revenue of $1.0 billion to $1.04 billion."

Harmony Reiterates 2026 Net Product Revenue Guidance of $1.0 to $1.04 Billion

Based on its first-half performance and current business trends, Harmony is reiterating its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.